PSMA for PET Imaging of Prostate Cancer

Ananya Ruangma, Suphansa Kijprayoon, Suthatip Ngokpol


18F-fluorodeoxyglucose (FDG or 18F-FDG) is the most widely used radiotracer forPositron Emission Tomography/Computed Tomography (PET/CT) imaging. However,using FDG for PET/CT imaging in prostate cancer is limited because a large fractionof prostate cancer shows limited FDG uptake. Previously, radiolabeled choline derivativesuch as 18F-fluorocholine and 11C-choline were considered as a more suitable alternativeto FDG for prostate cancer imaging. They are used as PET tracers for staging andrestaging of prostate cancer. Although the specificity of radiolabeled choline is quitehigh, the sensitivity is rather poor. Currently, targeting the prostate specific membraneantigen (PSMA) with molecular imaging agents has been increasingly investigated.PSMA is expressed in most prostate cancer and it is an ideal target for diagnosis andtreatment. There are many PSMA agents available nowadays. This article will givebrief overview about PSMA ligands for PET imaging and therapy of prostate cancer.

Keywords :
PSMA, PSMA imaging, Ga-68 PSMA

Address Correspondence to author:
Ananya Ruangma, PhDOncology Imaging & Nuclear Medical Department,Wattanosoth Hospital,Soi Soonvijai 7, NewPetchburi Rd,Bangkok 10310,

Received: May 22, 2018
Revision received: May 24, 2018
Accepted after revision: July 6, 2018
BKK Med J 2018;14(2): 95-100.

DOI: 10.31524/bkkmedj.2018.09.016

Full Text: